Insulin-like Growth Factors in a clinical setting: Review of IGF-I

Zdenek Frysak*, Jan Schovanek*, Maurizio Iacoboneb, David Karasek*

Background and Aims. Interest in growth hormone (GH) is inextricably linked to the need for in depth understanding of the somatomedins (insulin-like growth factors) which are polypeptides structurally similar to insulin and with broad physiological activity. To date, the most commonly known is Insulin-Like Growth Factor I (IGF-I). Despite considerable current knowledge of IGF-I, however, its bioactivity is incompletely understood. Measurement of IGF-I is of the utmost importance in the diagnosis and treatment of, for example acromegaly and growth hormone deficiency. The development of recombinant IGF-I, has allowed its use in such cases. Clinical practice, however, shows that few young/adult patients will benefit from treatment with the rIGF-I, mecasermin, given the number of adverse effects found. This review focuses on current knowledge mainly related to IGF-I and the use of its recombinant form (rIGF-I) in clinical practice. Several functions of IGF-II have been elucidated but their clinical significance is unclear.

Key words: Somatomedins, Insulin-Like Growth Factor I, II, IGF-I receptor, Human Growth Hormone, Recombinant Human Growth Hormone, Acid Labile Subunit, IGF Binding Proteins, Mecasermin, Insulin Receptor Isoform A, acromegaly, growth hormone deficiency

INTRODUCTION

Somatomedins refer to a group of polypeptides, today commonly known as Insulin-like Growth Factors (IGFs) that participate in a plethora of cellular processes. Their first discovery is attributed to Salmon and Daughaday, who in 1957, reported that GH injected into rat cartilage in vivo facilitated incorporation of sulfate ("sulfation factor"). However, the same process could not be induced in cell cultures1. These authors thus indirectly proved the existence of the somatomedins. Research in recent decades has uncovered the molecular structure of IGF and a number of its functions. Detailed description of the molecular structure was followed by synthesis of recombinant IGF-I that has facilitated its use in clinical practice.

Chemical structure and origin

The somatomedin group includes IGF-I and IGF-II which are around 50% identical to the amino acid precursor of insulin, proinsulin, the longest known structure of the three substances. IGF-I forms a single chain of 70 amino acids with three intermolecular disulfide bridges and a molecular weight of 7649 Daltons2. Although similar in structure, the three polypeptides have very different origins. Insulin, proinsulin more precisely, is formed by pancreatic β-cells, its activation is preceded by cleavage of the C-peptide with a half-life time calculated in minutes and it affects mainly the metabolism of hepatocytes, myocytes and adipose tissue cells. Unlike IGFs, insulin production, excretion and activity are not influenced by GH. These differences relate only marginally to our topic but they are reviewed by Rinderknecht et. al2. IGFs on the other hand, are formed in a far greater number of tissues and even today it is not possible to reliably identify which specific cells are responsible for their production. IGF-I (somatomedin C) and IGF-II mRNA can be detected by in situ hybridization histochemistry in the connective tissue of 14 organs (e.g. parasinusoidal liver cells, perichondrial cartilage, eye sclera, septa and connective tissue enveloping most organs) and also in human embryo tissues. Such cell structures are widely distributed in the human body. Thus, it is possible that IGFs are formed both locally and systemically, also creating the possibility of autocrine or paracrine effects3.

Genetics

Human genome studies have revealed two genes responsible for the production of IGFs. These exist as a single-copy gene. The largest amount of somatomedin mRNA is detected in the liver, as well as in the kidney, brain and myocardium. IGFs are released into circulation with subsequent binding to one of six IGF-binding proteins which modulate their activity. Binding proteins with affinity for IGF-I and IGF-II are locally produced in most tissues. A cDNA probe corresponding to mRNA encoding IGF-I was used for chromosomal assignment of the IGF-I gene. Interestingly, comparison of the chromosomal assignment of the IGF-I gene and two other members of the insulin gene family, with three c-ras oncogenes, revealed remarkable similarity of the two gene families.
The human gene encoding human insulin-like growth factor was identified on chromosome 12 (ref.⁵) as well as the proto-oncogene, c-Ki-ras (ref.⁵). Current knowledge suggests that IGF-I gene polymorphism affects human height, length of life and senses, such as sight and hearing⁶⁹.

**Receptors for IGF**

GH produced by the pituitary has a stimulatory effect on expression of the IGF-I gene, leading to the formation of IGF-I polypeptide chain. Increase in IGF-I levels reversely suppresses GH pituitary production. Both IGF-I and IGF-II have high binding affinity specific for the two sites of tyrosine kinase receptors like insulin. Although the intracellular response is similar to the one induced by insulin, IGFs influence growth and differentiation processes unlike insulin. IGFs reduce blood glucose levels but their effect is roughly about 5% of insulin’s. Another important factor affecting their immediate activity is their binding protein (BP), allowing transport of IGFs to specific receptors in target tissues. For IGF-I this is primarily binding to IGF-I BP3.

Activation of the insulin-like growth factor-I receptor (IGF-IR) pathway has also been found to be involved in the initiation and growth of cancers. For this reason, the IGF-I receptor (IGF-IR) has been studied as an anticancer target. However, monotherapy trials with IGF-IR targeted anti bodies or IGF-IR specific tyrosine kinase inhibitors, have been overall very disappointing in the clinical setting. It has become clear that intracellular signaling pathways are highly interconnected and complex¹⁰. Nevertheless, it is still possible that IGF-IR targeted therapy may be useful as adjuvant or the secondary target treatment of human cancers. Unfortunately, IGF-IR targeted therapy might fail due to activation of insulin receptor isoform A (IR-A) by IGF-II and consequently bypassing inhibited IGF-IR (ref.¹¹).

**Physiology of IGF-I**

The level of IGF-I production is influenced by many factors including gender and age. It is physiologically low at birth, with level increments in childhood and early adulthood, decreasing after 30 years of age. Production of IGF-I is stimulated by activated GH receptors; it has metabolic activities similar to those of insulin but also exerts its specific long term effects on cell proliferation and differentiation¹²¹⁴. Low levels of circulating IGF-I are associated with reduced insulin sensitivity¹⁵ and increased risk of impaired glucose tolerance or type 2 diabetes development¹⁶¹⁷. A correlation has been found between IGF-I and cardiovascular mortality¹⁸.

In malnourished individuals, there is a decrease or even disappearance of GH receptor sensitivity affecting IGF-I production. A model situation is the psychological disorder; anorexia nervosa. GH and also in parallel, IGF-I decreases with the disease progression as an effect of starvation on receptor function¹⁹. This phenomenon includes hypothalamic amenorrhea, relative hypercortisolemia, reduced stimulated levels of leptin, insulin, amylin and incretins (glucagon-like polypeptide-1, glucose-dependent insulotropic polypeptide), and conversely increased levels of adiponectin, ghrelin and peptide YY. Serious complications of anorexia nervosa include changes in bone microarchitecture with bone mineral density reduction, increased risk of fracture, neuro-cognitive impairment and the development of anxiety and depression. This could be seen as an indication for combined estrogen and IGF-I treatment in patients suffering from anorexia nervosa or those recovering from this condition¹⁰²².

The opposite situation is the overproduction of GH, with elevated IGF-I levels, in acromegaly. Although the relationship is not entirely linear, the normalization of IGF-I is considered as an essential indicator of activity, remission or cessation of the acromegalic process. Crucially important for maintaining the balance in the system of the circulating IGF/IGF-BP is ALS (acid-labile subunit). ALS is a critical component in the development of a large reservoir of IGFs by extending its half-life from 10 min of the free form to 30-90 min in binary complexes (early periods of human life), later to more than 12 h, when bound into tertiary complexes¹³²⁵. Patients lacking ALS have significantly reduced serum IGF-I and IGFBP-3 leading to moderate growth retardation (height SDS -2 to -3 SDS before and during puberty). Twenty one male patients were described as lacking ALS as a result of 16 unique homozygous or compound heterozygous inactivating mutations of the IGF ALS gene. These boys had delayed puberty and varying degrees of insulin resistance. In the assessment of a short stature child, ALS deficiency should be considered in those presenting with a normal response to GH stimulation test, low IGF-I levels associated with more profoundly reduced IGFBP-3 levels, a mild growth retardation (apparently out of proportion to the degree of IGF-I and IGFBP-3 deficits), lack of response to IGF generation test and insulin insensitivity²⁸.

**Methods of IGF-I measurement**

There are a number of commercially available immunoassay kits for measuring IGF-I as well as GH and IGFBP-3 using IRMA, RIA and ELISA methods. Several assays have traditionally been used to measure IGF-I bioactivity but have not become routine in laboratory practice owing to technical problems and high costs. Thus, there is still a need for rapid, technically simple and accurate assay to determine IGF-I bioactivity⁷. The main problem is standardization of methods regarding the issue of interference with IGF-I binding proteins, causing inaccurate and therefore unreliable results²⁹. The binding proteins can be removed by acid gel filtration chromatography³⁰. This procedure is however laborious and expensive. Hence, commercial laboratories do not use it, preferring acid displacement of binding proteins and then precipitated with ethanol in the investigated material. For a valid assay, only IGF-I should remain in the sample³¹. The incomplete removal of small molecules of binding proteins primarily not bound to ALS causes measurement errors. Recently, commercial immunoassays for IGF-I based on competitive non-sandwich approach methods have become available. Use of two antibodies,
refines the result and the system allows for automated sample processing but the methodology is still based on acid/ethanol precipitation or the addition of IGF-II as a precaution against the interfering effects of the remaining binding proteins. Overall, there are difficulties in results comparison between commercial IGF-I assays due to lack of standardization. This aside, IGF-I corrected for patient age is a basic laboratory marker in the differential diagnosis of conditions associated with excess, deficiency of or resistance to GH.

**Dual use of IGF-I measurement in clinical practice**

Firstly, IGF-I has acquired an irreplaceable position in the diagnosis of acromegaly and gigantism. Suspicions of the process is based on the presence of clinical symptoms, detailed elsewhere in the literature. Increased levels of IGF-I predicates active disease. If a randomly taken sample has a GH level below 1.0 ng/mL, active process can be practically excluded. Diagnosis is confirmed unequivocally by a modified oral glucose tolerance test (100 g glucose) with GH level monitoring every half hour for the following 2 or 3 hours. In case that, after the glucose load, the GH level does not decrease below 0.4 ng/mL (ref.38). Initial check of IGF-I combined with three independent samples of GH serum levels are generally accepted parameters of active acromegaly and gigantism. Administration of somatostatin analogs has significantly expanded the options for acromegaly treatment with regular checks of IGF-I levels as a reliable indicator of therapeutic response. Its importance has resulted in a consensual treatment protocol describing long-acting somatostatin analogue treatment before surgery for pituitary adenoma in patients with acromegaly in the Czech Republic (unpublished data).

Secondly, IGF-I corrected for patient’s age is commonly used as an indicator for substitution effectiveness of recombinant human growth hormone (rhGH), both in pediatric patients, where the dose of rhGH (approximately 40 mg/kg of body weight) is to ensure dynamic and optimal growth of a child patient. In adults, the applied schema and rhGH dosing meets specific requirements, as follows: in the case of men, the usual adult dosage ranges around 0.1-0.3 mg/kg of body weight. In woman without estrogen deficiency, a single evening dose could even double the male’s dose. Lack of GH in adulthood as a single hormone deficiency must be suspected if IGF-I levels are below the age group standards. Most patients with issues affecting the hypothalamic-pituitary axes are indicated for hormone evaluation testing. Patients at risk are those with a history of past surgery, radiotherapy or inflammatory brain process i.e. encephalitis. The insulin tolerance test (ITT) in patients with low GH levels (< 3μg/L) is considered as a gold standard and as a test confirming the diagnosis of GH deficiency. If ITT is contraindicated (for unacceptable risk of hypoglycemia), there are other optional tests, e.g. an arginine test combined with an administration of single dose of GHRH (Growth hormone releasing hormone); L-Dopa and glucagon stimulation tests. The validity of the latter two stimulation tests, is however relative in the literature. Clinical experience has confirmed that lack of 3 pituitary hormones other than GH, implies with almost certainty also complete or at least significant GH deficiency.

**IGF-I as a Therapeutic Agent**

In severe primary IGF-I deficiency, the unresponsiveness of hepatic GH receptors to normal GH stimulation, leads to reduced levels of endogenous IGF-I and consequently decreased growth (cells, skeleton, and organs). Megasom ingestion - an insulin-like growth factor produced by recombinant DNA technology (rIGF-I) - might be the key to replace lack of endogenous IGF-I (ref.39). Endogenous IGF-I suppresses liver glucose production, stimulates peripheral glucose utilization and has an inhibitory effect on insulin secretion. The wide spectrum of its activities and biological effects on many different tissues holds promise for its use in a wide range of indications e.g. osteoporosis, diabetes mellitus and insulin resistance, GH insensitivity, obesity, various catabolic states and also possibly for some neuromuscular disorders. A typical representative is the Laron syndrome described in a number of studies. This includes postnatal growth failure, moderate to severe bone age delay relative to chronological age, short limb length in relation to trunk and delayed puberty by 3 to 7 years. Intellectual development is normal or modestly impaired. Morphological changes can be present in the head, neck and face region. Slower than normal is dentition and patients have a blue sclera. Sexual function and fertility are normal. They suffer from disorders of lipid metabolism and insulin resistance. Children of any age group develop osteopenia and are prone to hypoglycemia with metabolic obesity.

Another indication for rIGF-I use appears to be insulin resistance, insulin-dependent diabetes mellitus and currently also non-insulin dependent diabetes mellitus. In the case of insulin resistance, it is believed that the IGF-I molecule which is structurally similar to that of insulin can block the action of the insulin receptor. Administration of rIGF-I to patients with type 2 diabetes, resulted in a 3.4-fold improvement in insulin sensitivity. Whether diabetic patients receive insulin or oral hypoglycemic agents, it means that the glycemic level can be improved substantially by rIGF-I injections. In these patients, it is believed that IGF-I acts through facilitation of glucose utilization by peripheral tissues and also by increased insulin secretion from the pancreatic β-cells. Patients with mutations in the insulin-receptor gene or in genes related to the signal-transduction pathways, have different phenotypes including lipoatrophy syndrome or type A insulin resistance with mutations of the insulin-receptor gene, pseudocromegaloaidism, leprechaunism, and the Rabson-Mendenhall syndrome.

Both clinical trials and everyday practice have confirmed that rhGH/rIGF-I positively affects body composition. It reduces the abdominal circumference as well as the amount of visceral fat. It is important to highlight that rhGH is not approved for obesity treatment. Nevertheless, it can be reasonably assumed that rhGH, IGF-I or their analogues (tesamorelin) could help to effectively intervene in the metabolic process in obese patients.
In catabolic patients, anabolic hormone treatment results in improved whole body protein balance but use of rhGH and IGF-I treatment in critically ill patients is controversial. The Growth Hormone Research Society has recommended the cessation of rhGH (and by inference rIGF-I) use during critical illness.

**Practical aspects of rIGF-I therapy**

The Food and Drug Administration (FDA) has approved clinical use of mecasermin, a recombinant human IGF-I analog intended for subcutaneous application and also of mecasermin rinfabate, a binary complex of equinomolar IGF-I and IGFBP-3. However, only mecasermin is available in the Czech Republic. It is used for children ≥ 2 years old and also for adolescents. The recommended initial dose is 0.04 to 0.08 mg/kg twice a day. If well-tolerated for a week, the dose can be increased by 0.04 mg/kg up to 0.12 mg/kg twice a day. The drug must be taken within 20 min after a meal. If the patient is unable to eat, rIGF-I should be omitted. If hypoglycemia occurs despite compliance with dietary regimen, the dose of mecasermin must be reduced. Mecasermin is not for intravenous use and is contraindicated in cases of hyperglycemia, after closure of the growth zones and in case of suspicion of an active neoplastic process. Initial enthusiasm for rIGF-I treatment vanished with the description of its numerous adverse effects. In addition to hypoglycemia, retinal edema, Bell's palsy, and severe myalgias have been reported. The frequency of these adverse effects can be usually reduced with rIGF-I doses of 0.04 mg/kg twice a day only or less.

rIGF-I is not currently approved for the treatment of type 2 diabetes but it has been effectively used for blood glucose control in patients with rare extreme insulin resistance syndromes. Treatment with rIGF-I is also effective in patients with GH insensitivity due to GH receptor mutations and in patients of short stature and very low serum IGF-I (e.g., < 2.5 SDS) (ref.52). Adverse effects, such as enhanced growth of tonsils, soft facial tissue, and kidneys, have been observed in some children. Currently, rIGF-I treatment is approved for children with short stature (< -3.0 SDS) or IGF-I level below -3.0 SDS but normal to elevated GH levels.

**IGF-II**

IGF-II plays an important role in fetal and postnatal development. Not much is known about its physiological functions in adulthood. It is confirmed that tumor cells produce large amounts of IGF-II as a prohormone functioning in autocrine manner. High levels of IGF-II inhibit GH production. The low affinity of IGF-II to its binding proteins causes a high level of the free hormone which in turn results in suppression of glucose uptake by hepatocytes. This results in a tendency to hypoglycemia with preferential storage of glucose in myocytes. Removal of the tumor mass or radiation therapy are accompanied by normalization of IGF-II levels and restitution of normoglycemia. Rodent experiments have shown interesting possibilities for the use of IGF-II as a cognitive enhancing agent. However, there are many IGF-II functions yet to be elucidated. The clinical importance of such research is not entirely clear and strong motivation for it is lacking.

**REFERENCES**


